Kite Pharma | search
Click here to view Kite Pharma news from 60+ newspapers.
Bookmark or Share- U.S. FDA Approves Kite’s Tecartus® as the First and Only Car ...October 01, 2021. U.S. FDA Approves Kite’s Tecartus® as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia. -- 65% of Patients Achieved Overall Complete Remission with Tecartus -- -- High Unmet Need: Fifty Percent of Adult Patients Will Relapse on Currently Available Treatments --
- Transformational Cancer Treatment | Kite PharmaTransformational Cancer Treatment. At Kite, our singular focus is cell therapy to treat and potentially cure cancer. Our goal is to bring the promise of cell therapy to as many eligible patients as possible who may benefit. We believe cell therapy has the ability to change the way cancer is treated. Our industry-leading cell therapy technology ...
- Announcement: Kite Pharma Acquisition | GileadGilead Completes Acquisition of Kite Pharma. Gilead Sciences has completed the acquisition of Kite Pharma and is proud to officially welcome Kite’s more than 700 talented employees to the Gilead organization – for further details on the acquisition, click here.
- Kite Receives U.S. FDA Approval of Manufacturing Process ...SANTA MONICA, Calif., January 30, 2024 -- ( BUSINESS WIRE )--Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a manufacturing...
- Kite Pharma - WikipediaKite Pharma is an American biotechnology company that develops cancer immunotherapy products, with a primary focus on genetically engineered autologous CAR T cell therapy, a cell-based therapy which relies on chimeric antigen receptors and T cells.
More
